Geovax Labs (OTCMKTS: GOVX) is one of 32 public companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare Geovax Labs to related companies based on the strength of its dividends, earnings, risk, institutional ownership, profitability, valuation and analyst recommendations.
Valuation and Earnings
This table compares Geovax Labs and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Geovax Labs||$1.08 million||-$2.17 million||-0.67|
|Geovax Labs Competitors||$968.26 million||$63.67 million||12.57|
Volatility and Risk
Geovax Labs has a beta of 0.1, meaning that its share price is 90% less volatile than the S&P 500. Comparatively, Geovax Labs’ competitors have a beta of 4.22, meaning that their average share price is 322% more volatile than the S&P 500.
Institutional & Insider Ownership
0.1% of Geovax Labs shares are held by institutional investors. Comparatively, 47.1% of shares of all “Commercial physical research” companies are held by institutional investors. 2.1% of Geovax Labs shares are held by company insiders. Comparatively, 16.4% of shares of all “Commercial physical research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of current ratings for Geovax Labs and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Geovax Labs Competitors||125||591||1365||55||2.63|
As a group, “Commercial physical research” companies have a potential upside of 14.32%. Given Geovax Labs’ competitors higher possible upside, analysts plainly believe Geovax Labs has less favorable growth aspects than its competitors.
This table compares Geovax Labs and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Geovax Labs Competitors||-282.28%||-85.70%||-34.36%|
Geovax Labs competitors beat Geovax Labs on 8 of the 9 factors compared.
Geovax Labs Company Profile
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines for infectious diseases and cancer in the United States and internationally. The company through its patented Modified Vaccinia Ankara-Virus Like Particle vaccine platform develops various vaccines. It is developing various vaccines that are in human clinical trials, and preclinical research and development phases, including vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; United States Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; Peking University; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; and CaroGen Corporation. GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.
Receive News & Ratings for Geovax Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geovax Labs and related companies with MarketBeat.com's FREE daily email newsletter.